Refractory epilepsy is a major health problem: roughly one-third of epilepsy patients (or approximately one in 300 people) have seizures that do not respond to standard medical treatments. Nutritional therapy, specifically a low carbohydrate ketogenic diet, can be an effective treatment for these patients indicating a strong link between metabolism and seizure susceptibility but the strict diet is quite difficult, and the mechanism(s) of efficacy in animal models have remained elusive. This project will explore the link between metabolism and seizure susceptibility through an alternative approach that does not require dietary manipulation. We have found that mutations of a single gene, Bad, can produce striking resistance to seizures in mice. The BAD protein is best known for its role in regulating the mitochondrial pathways of apoptosis, but the pattern of mutational effects indicates that seizure resistance is related instead to the newly identified non-apoptotic role of BAD in metabolism. BAD has been found to regulate the cellular choice of fuel consumption through a phosphorylation dependent mechanism that enables metabolism of glucose as compared with other carbon substrates such as ketone bodies and fatty acids. The studies proposed here test the hypothesis that BAD reprograms energy metabolism to determine the choice of fuel substrates in the brain, which may serve as a trigger for changes in neuronal excitability and seizure susceptibility. We will employ a multi-disciplinary approach to test this hypothesis at three levels.
In aim 1, we will examine BAD-dependent alterations in cellular energy metabolism in neurons and glial cells, using strategies that include real time assessment of mitochondrial fuel oxidation, live cell imaging using novel metabolic biosensors, and mass spectrometry based profiling of metabolite byproducts of fuel consumption. These studies will dissect the mechanistic underpinnings of BAD modulation of neurometabolism that may influence excitability.
In aim 2, we will perform electrophysiological studies in brain slices to directly measure the consequences of BAD manipulation for cellular and network excitability in brain slices, guided by our preliminary findings that suggest increased activity of metabolically sensitive KATP channels in neurons of Bad mutant mice.
In aim 3, we will test the ability of Bad mutations to influence seizures in vivo, using continuous video-EEG monitoring, in several acute seizure models as well as in a mouse genetic model of chronic epilepsy with spontaneous seizures. Taken together, these aims will allow vertical integration in understanding BAD s effect on neuroenergetics and seizure susceptibility. In addition to genetic tools for manipulating metabolism by mutations in the Bad gene, novel pharmacomimetic compounds modeled after the metabolically active domain of the BAD protein will be used at each stage of the studies. These compounds may offer a future path for translating our improved understanding of the link between metabolism and excitability into potential new therapies for epilepsy.

Public Health Relevance

Manipulation of glucose metabolism through mutations in a single gene, Bad, confers profound resistance to epileptic seizures in mice. This research will examine how these mutations alter metabolism in the brain and subsequently affect seizure susceptibility. The studies will also employ novel pharmacological tools that mimic these mutations in order to test their potential therapeutic benefits in treating epilepsy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
High Priority, Short Term Project Award (R56)
Project #
1R56NS072142-01A1
Application #
8332961
Study Section
Clinical Neuroplasticity and Neurotransmitters Study Section (CNNT)
Program Officer
Whittemore, Vicky R
Project Start
2011-09-30
Project End
2013-06-30
Budget Start
2011-09-30
Budget End
2013-06-30
Support Year
1
Fiscal Year
2011
Total Cost
$602,067
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Ribeiro, Sofia M; Giménez-Cassina, Alfredo; Danial, Nika N (2015) Measurement of mitochondrial oxygen consumption rates in mouse primary neurons and astrocytes. Methods Mol Biol 1241:59-69
Stanley, Illana A; Ribeiro, Sofia M; Giménez-Cassina, Alfredo et al. (2014) Changing appetites: the adaptive advantages of fuel choice. Trends Cell Biol 24:118-27
Lutas, Andrew; Yellen, Gary (2013) The ketogenic diet: metabolic influences on brain excitability and epilepsy. Trends Neurosci 36:32-40
Giménez-Cassina, Alfredo; Martínez-François, Juan Ramón; Fisher, Jill K et al. (2012) BAD-dependent regulation of fuel metabolism and K(ATP) channel activity confers resistance to epileptic seizures. Neuron 74:719-30